Cassava Sciences | PTIE - Net Income


Cassava Sciences reported $-10.33M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Abbott USD 928M 149M Jun/2026
Amgen USD 1.82B 486M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
Cara Therapeutics USD -5.53M 621K Sep/2025
Cassava Sciences USD -10.33M 2.21M Mar/2026
Eisai JPY -3.25B 20.43B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Geron USD -3.64M 27.5M Mar/2026
J&J USD 5.53B 299M Jun/2026
Merck USD -4.24B 7.2B Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025